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Introduction: With increasing availability of different treatments for chronic obstructive
pulmonary disease (COPD), we sought to understand patient preferences for COPD treat-
ment in the UK, USA, and Germany using a discrete choice experiment (DCE).
Methods: Qualitative research identified six attributes associated with COPD maintenance
treatments: ease of inhaler use, exacerbation frequency, frequency of inhaler use, number of
different inhalers used, side effect frequency, and out-of-pocket costs. A DCE using these
attributes, with three levels each, was designed and tested through cognitive interviews and
piloting. It comprised 18 choice sets, selected using a D-efficient experimental design.
Demographics and disease history were collected and the final DCE survey was completed
online by participants recruited from panels in the UK, USA and Germany. Responses were
analyzed using mixed logit models, with results expressed as odds ratios (ORs).
Results: Overall, 450 participants (150 per country) completed the DCE; most (UK and
Germany, 97.3%; USA, 98.0%) were included in the final analysis. Based on relative attribute
importance, avoidance of side effects was found to be most important (UK: OR 11.65; USA:
OR 7.17; Germany: OR 11.45; all p<0.0001), followed by the likelihood of fewer exacerba-
tions (UK: OR 2.22; USA: OR 1.63; Germany: OR 2.54; all p<0.0001) and increased ease of
use (UK: OR 1.84; USA: OR 1.84; Germany: OR 1.60; all p<0.0001). Number of inhalers, out-
of-pocket costs, and frequency of inhaler use were found to be less important. Preferences were
relatively consistent across the three countries. All participants required a reduction in exacer-
bations to accept more frequent inhaler use or use of more inhalers.
Conclusion: When selecting COPD treatment, individuals assigned the highest value to the
avoidance of side effects, experiencing fewer exacerbations, and ease of inhaler use.
Ensuring that patients’ preferences are considered may encourage treatment compliance.
Keywords: discrete choice experiment, DCE, symptomatic chronic obstructive pulmonary
disease, COPD, stated-preference methods
Plain Language Summary
Chronic obstructive pulmonary disease (COPD) treatments can differ widely based on a number
of characteristics, for example the number of inhalers required, the number of times a patient
needs to use their inhaler per day, associated side effects, and out-of-pocket costs.
Using an online treatment choice survey designed to assess preference for treatment
characteristics, this study demonstrates that in patients with COPD in the United Kingdom
(UK), United States of America (USA), and Germany, the importance of these characteristics
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varies. The strongest preference of these patients was for treat-
ments associated with fewer side effects, followed by treatments
that reduced the number of COPD exacerbations they were likely
to experience per year. Patients also preferred treatments that
were easy to use.
The findings from this study may help doctors to understand
their patients’ preferences better and prescribe treatment regi-
mens that patients may be more likely to follow. This may
have a positive impact on treatment effectiveness.
Introduction
Chronic obstructive pulmonary disease (COPD) is asso-
ciated with high morbidity and is a common cause of death
globally.1 Depending on the severity of COPD,
a combination of β2-agonists (which may be short-acting
[SABA] or long-acting [LABA]), long-acting muscarinic
antagonists (LAMA), and inhaled corticosteroids (ICS)
has been shown to improve lung function, symptoms,
and health status, and to reduce exacerbations vs ICS/
LABA and LAMA monotherapy in patients with COPD
and a history of exacerbations.2 While triple combination
therapy with ICS, LAMA and LABA has demonstrated
benefits over a combination of ICS/LABA or LAMA
monotherapy alone,2 patients have, until recently, been
required to use at least two inhalers to deliver the three
molecules; these three drug classes are now available
combined in single-inhaler triple therapy.3–5
On account of the wide variety of existing treatments
for COPD, which can differ by dosing regimen, number of
required inhalers, and potential side effects, an improved
understanding of patient preferences, and what drives
these preferences, may help to inform physician prescrib-
ing decisions. As part of a wider effort to understand
patient preferences in both the United States of America
(USA) and Europe, we sought to develop a discrete choice
experiment (DCE) for the assessment of patient prefer-
ences for characteristics of COPD treatments in the UK,
USA, and Germany. A DCE is a quantitative method that
allows the relative strength of patient preferences for the
attributes of a treatment or product to be compared with
respect to each other, and shows how these attributes may
impact patient choices.6 Here we present the methodology
and results of the DCE.
Methods
Overall Study Design
The development and implementation of the DCE to inves-
tigate patient preferences for characteristics of treatment
involved four key stages: a qualitative phase based around
interviews with COPD patients; a DCE design phase; a pilot
survey to test the DCE design; and the final DCE.
Institutional review board (IRB) approval (Salus IRB,
Texas, USA) was obtained for research carried out in all
three countries prior to commencing recruitment and elec-
tronic informed consent was obtained from all participants
prior to study initiation.
Qualitative Phase
Initial qualitative research (see Supplementary material)
identified six key attributes of COPD treatment for inclu-
sion in the DCE: ease of inhaler use, frequency of exacer-
bations, frequency of inhaler use (number of times
per day), number of different inhalers used, frequency of
side effects, and extent of out-of-pocket costs (USA and
Germany only) (Table 1). Cost was omitted as an attribute
in the UK survey, since patients in the UK pay a standard
per-prescription fee, regardless of treatment type;7 there-
fore, cost factors were not considered to play a role in
determining treatment preference for participants in the
UK. Three levels were used for each attribute; this was
determined based on data derived from clinician and
patient interviews, and patient focus groups, along with
feedback from respiratory experts and relevant literature.
Study Population for the Pilot Survey and
DCE
Individuals with a self-reported diagnosis of COPD were
recruited between February 2017 and February 2018 by
Global Perspectives, a patient recruitment agency, for both
the initial pilot survey and subsequent DCE. Eligible par-
ticipants were aged ≥40 years with a diagnosis of moder-
ate-to-severe COPD (COPD Assessment Test [CAT] score
≥10 or modified Medical Research Council [mMRC]
Dyspnea Scale score ≥2),8,9 and were prescribed either
an ICS/LABA, LAMA/LABA, ICS/LAMA/LABA, or
LAMA alone. Participants were residents of the UK,
USA, or Germany, fluent in the language of their country
of residence, and had access to the internet. Participants
were recruited through established channels in each coun-
try: in Germany, the recruitment agency used their own
patient database, social media, and patient key opinion
leaders to recruit; consumer and medical recruiter net-
works were utilized in the UK, alongside support groups
and nurses; in the USA, the recruiters’ proprietary patient
database was used.
Lewis et al Dovepress
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DCE Design
A D-efficient experimental design6 determining the exact
choice sets in the pilot survey was constructed using
Ngene software.10 This method was selected to maximize
the statistical efficiency in measuring the main effects. One
dominant choice question (in which one scenario is objec-
tively better than the other) was included in each survey to
check for logical responses. Only participants who
answered the logical choice test correctly were included
in the final model. Attribute levels were specified as ordi-
nal to minimize the number of dominant choice sets.11
A consistency test was also included in the survey
whereby the third or fourth choice set was repeated at
the end of the survey to check for consistency in
responses.12,13
DCE Testing
Draft versions of the DCE survey were first tested in
participants with symptomatic COPD in each country
(n=6 per country) by way of cognitive interviews to eval-
uate general readability of the country-specific DCE sur-
veys and item comprehension. Review of the data from the
cognitive interviews confirmed that no major changes to
the DCE survey were required; however, a number of
simple changes were made. Translations of the levels in
each attribute, for example, were reviewed and adjusted to
ensure they would not be construed as questions by parti-
cipants completing the DCE survey in German. Similarly,
minor adjustments were made to the wording of the DCE
survey to ensure that participants would not expect to be
asked qualitative questions regarding their experience of
COPD and their medications, and to ensure that patients
considered only maintenance therapy in their answers for
the survey. Additionally, an example of a DCE choice set
was included in the survey to prepare participants for the
type of questions they would be asked. Finally, for the data
analysis, the reference level for each attribute was changed
from the “best” to the “worst” between the pilot and the
final analysis, to allow for more intuitive interpretation in
the main analysis.
Pilot Survey
To confirm the feasibility of the DCE and refine the under-
lying design, an initial pilot survey was carried out. A total
of 54 participants was included in the pilot survey (UK,
n=20; USA, n=14; Germany, n=20). Data collected
included demographic characteristics and responses to
the DCE choice sets. Full details of the analytical methods
and results of the pilot survey are provided in the
Supplementary material and Supplementary Tables S1–S3.
Final DCE
The final DCE contained 18 choice sets that each participant
was required to complete (Supplementary Table S4), includ-
ing one dominant task to test the logic of their choices. One
additional repeated choice set was also included as
a consistency check. While the 18 choice sets for the USA
and Germany were identical (see Table 2 for an example
Table 1 Discrete Choice Experiment (DCE) Attributes and Levels
Attribute Level 1 Level 2 Level 3
Ease of inhaler use Likely to make no mistakes Likely to make some mistakes Likely to make a lot of mistakes
Number of exacerbations
per year (efficacy)
Likely to experience no
exacerbations (flare-ups) in the
next year
Likely to experience one
exacerbation (flare-up) in the
next year
Likely to experience two
exacerbations (flare-ups) in the
next year
Number of times per day you
need to take the medication
Once a day Twice a day Three times a day
Number of maintenance/
preventer inhalers
One inhaler Two different inhalers Three different inhalers
Out-of-pocket costs (USA and
Germany only)
No change in cost of medication 5% decrease in cost of medicationa 10% decrease in cost of medicationa
Likelihood of side effects Likely to experience no side effects Likely to experience some side
effects
Likely to experience a lot of side
effects
Notes: aCost reduction relative to cost of current medication (USA and Germany only).
Abbreviations: DCE, discrete choice experiment; USA, United States of America.
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choice set), the cost attribute was omitted prior to designing
the UK survey. A D-efficient design was used to maximize
the statistical efficiency in measuring the main effects, with
attribute levels specified as ordinal to minimize the number
of dominant choice sets (in which one scenario is objectively
better than the other). The survey was administered online
and included instructions for participants, an example ques-
tion (choice set, see Supplementary Figure S1), and socio-
demographic and medical history questions.
Final DCE Data Analysis
Demographic data were summarized in SAS software,
version 9.4, using descriptive statistics (mean, standard
deviation [SD] or median, interquartile range [IQR] for
continuous variables, and numbers and percentages for
categorical variables). The analysis of the DCE was con-
ducted using R statistical software,14 version 1.1.414, with
estimates of the impact of each attribute (independent
variable) on the participants’ choices (dependent variable)
obtained from mixed logit models converted into odds
ratios (ORs) and associated 95% confidence intervals
(CIs). Exacerbations, frequency, number of inhalers, and
out-of-pocket costs were coded as continuous variables.
Ease of use and side effects were treated as categorical
variables, with the “worst” level used as reference. As an
example, greatest frequency of exacerbations was the
reference level for the frequency of exacerbations attri-
bute. A sample size of n=150 per country was targeted,
based on the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) Task Force publication,6
which demonstrated that the precision of parameter esti-
mates increases rapidly at sample sizes less than 150, and
flattens out at approximately 300 observations. With
a sample size of n=150, separate analyses could be con-
ducted in each of the three countries but formal statistical
comparisons were not made between countries.
Additional analyses were conducted to explore the
relative importance of different attributes in the decision-
making process, the extent to which different individual
characteristics (eg, age, gender, and severity of illness)
influence the strength of these preferences, and the mar-
ginal rate of substitution (MRS), or how much of one
attribute individuals are willing to give up for changes in
another. The relative importance of each attribute was
calculated by determining the difference between the mini-
mum and maximum coefficients of each attribute.15 To
estimate the relative attribute importance as a percentage,
the difference was divided by the sum of the differences
between all the coefficients of all the attributes. Using
these data, a ranking was provided for the attributes. An
exploratory analysis was also conducted to assess prefer-
ence heterogeneity by incorporating additional interaction
terms between attributes or individual characteristics and
an attribute. The MRS for out-of-pocket costs and number
of exacerbations was calculated (details provided in the
Supplementary material) using the results from
a multinomial logit model. The MRS was used to provide
a measure of (1) the reduction in exacerbations required to
accept a treatment with a higher number of required inha-
lers or a higher number of uses per day, and (2) the overall
cost reduction required to accept a treatment with a higher
number of required inhalers, a higher frequency of use
per day or an increase in exacerbations.
Table 2 Example Discrete Choice Experiment (DCE) Choice Set
What Maintenance/Preventer Medication for COPDWould
You Choose? Please Imagine You Can Choose Only One and
These Were Your Only Options.
A B
Inhaler ease of use Likely to make no
mistakes
Likely to make a lot
of mistakes
Exacerbations
(flare-ups)
Likely to
experience one
exacerbation
(flare-up) in
the next year
Likely to experience two
exacerbations (flare-ups)
in the next year
Number of times
per day you need to
take medication
Once a day Twice a day
Number of
maintenance/
preventer inhalers
Three different
inhalers
Two different inhalers
Out-of-pocket cost
per month
5% decrease in
cost
of medicationa
No change in
cost of medication
Side effects Likely to
experience
some side effects
Likely to experience no
side effects
Would You Prefer Your Choice (A or B) More Than Your Current
COPD Maintenance Medication?
Yes No
Notes: aCost reduction relative to cost of current medication (USA and Germany
only).
Abbreviations: COPD, chronic obstructive pulmonary disease; DCE, discrete
choice experiment.
Lewis et al Dovepress
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Results
Overall, 450 participants took part in the DCE (UK,
n=150; USA, n=150; Germany, n=150). Participants were
split fairly evenly between males and females (56% vs
44%, respectively) and had a median age of 64 years,
with a median time since diagnosis of approximately 6
years (Table 3; additional baseline characteristics and
treatment history are presented in Supplementary Tables
S5 and S6, respectively). All participants had been receiv-
ing maintenance treatment for approximately 3 years; in
total, 21% of participants were not using rescue medica-
tion at the time of the survey.
Effect of Treatment Attributes on Choice
Results between the conditional logit and mixed logit model
were consistent. Here we present the results of the mixed
logit model, as per current standard practice, in order to
account for unobserved preference heterogeneity. Across all
attributes for the mixed logit model (random effects for
each attribute), ORs were greater than 1, showing that for
an improvement in the attribute level (eg, from “a lot” to
“some” side effects) there was an increased likelihood of
participants preferring the treatment (Figure 1 and
Supplementary Table S7). Of the 150 UK participants,
146 (97%) answered the logical choice test correctly and
were included in the final model. The strongest drivers of
treatment choice, associated with the highest ORs, were an
avoidance of side effects (OR 11.65 [p<0.0001] when par-
ticipants considered no side effects vs a lot of side effects)
and a reduction in the number of exacerbations (OR 2.22
[p<0.0001] for each unit reduction per year; Figure 1 and
Supplementary Table S7). Of the 150 USA respondents,
147 (98%) answered the logical choice test correctly and
were included in the final model. The strongest drivers of
treatment choice were an avoidance of side effects (OR 7.17
[p<0.0001] when participants considered no side effects vs
a lot of side effects) and ease of inhaler use (OR 1.84
[p<0.0001] when participants considered no mistakes vs
a lot of mistakes; Figure 1 and Supplementary Table S7).
Of the 150 German participants, 146 (97%) answered the
logical choice test correctly and were included in the final
model. The strongest drivers of treatment choice were an
avoidance of side effects (OR 11.45 [p<0.0001] when par-
ticipants considered no side effects vs a lot of side effects)
and a reduction in exacerbations (OR 2.54 [p<0.0001] for
each unit reduction per year; Figure 1 and Supplementary
Table S7).
Assessment of preference heterogeneity within each coun-
try showed that the participants’ preferred treatment attributes
were relatively similar (Supplementary Table S8). In none of
the countries was there a significant interaction between par-
ticipant age and the ease of inhaler use attribute, the time since
diagnosis and the number of side effects experienced attribute,
and the current number of inhalers and number of inhalers
attribute (Supplementary Table S8). However, a significant
interaction was noted in the UK (–0.1175, p=0.0002) and
Germany (–0.0908, p=0.0043) between the participants’
exacerbation history and the number of exacerbations
Table 3 Participant Characteristics
Total
(N=450)
UK
(n=150)
USA
(n=150)
Germany
(n=150)
Age, Years
Median (IQR) 64.0
(58.0–71.0)
67.0
(59.0–71.0)
66.0
(59.0–73.0)
60.0
(55.0–65.0)
Sex, n (%)
Male 254 (56.4) 88 (58.7) 76 (50.7) 90 (60.0)
Female 196 (43.6) 62 (41.3) 74 (49.3) 60 (40.0)
Smoking Status,
n (%)
Former 260 (57.8) 78 (52.0) 106 (70.7) 76 (50.7)
Current 179 (39.8) 69 (46.0) 39 (26.0) 71 (47.3)
Never 11 (2.4) 3 (2.0) 5 (3.3) 3 (2.0)
Time Since
Diagnosis, Years
Median (IQR) 6.00
(3.0–10.0)
5.00
(3.0–10.0)
7.00
(4.0–11.0)
5.00
(3.0–10.0)
mMRC Dyspnea
Scale Score,a n (%)
0 28 (6.2) 9 (6.0) 15 (10.0) 4 (2.7)
1 177 (39.3) 56 (37.3) 65 (43.3) 56 (37.3)
2 156 (34.7) 54 (36.0) 48 (32.0) 54 (36.0)
3 71 (15.8) 23 (15.3) 18 (12.0) 30 (20.0)
4 18 (4.0) 8 (5.3) 4 (2.7) 6 (4.0)
CAT Score
Mean (SD) 22.9 (7.2) 23.3 (7.8) 21.1 (6.9) 24.2 (6.8)
Exacerbations in
the Past Year, n (%)
0 157 (34.9) 53 (35.3) 54 (36.0) 50 (33.3)
1 107 (23.8) 32 (21.3) 34 (22.7) 41 (27.3)
2 105 (23.3) 38 (25.3) 31 (20.7) 36 (24.0)
≥3 81 (18.0) 27 (18.0) 31 (20.7) 23 (15.3)
Notes: aThe mMRC Dyspnea Scale is 0: no breathlessness except on strenuous
exercise; 1: short of breath when hurrying on level ground or walking up a slight hill;
2: slower than people of the same age because of breathlessness, or need to stop
for breath when walking at own pace; 3: stop for breath after walking about 100
yards or after a few minutes on level ground; 4: too breathless to leave the house or
breathless when dressing.
Abbreviations: CAT, COPD Assessment Test; IQR, interquartile range; mMRC,
modified Medical Research Council; SD, standard deviation; UK, United Kingdom;
USA, United States of America.
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attribute, indicating that participants who had experienced
more exacerbations in the past assigned less value to
a decrease in exacerbations of <2 in the next year.
Attribute Relative Importance
Overall, avoidance of side effects whilst on treatment was
ranked as the most important attribute across all three
countries (relative importance: UK, 59%; USA, 51%;
Germany, 55%), followed by reduction in exacerbations
and ease of inhaler use (means of 18% and 14% across
countries, respectively). The mean relative importance of
number of inhalers, out-of-pocket costs, and frequency of
use (number of times per day) was 7%, 5%, and 5%,
respectively. While these trends were generally similar
between countries, participants in the USA did assign
more importance to ease of inhaler use (16%) vs those in
the UK (13%) and Germany (11%).
Marginal Rates of Substitution
Participants in the USA and Germany (analysis not applic-
able to the UK) would require a reduction in out-of-pocket
costs if they were required to tolerate additional exacerba-
tions (a 12% and 21% cost reduction per exacerbation
per year, respectively). A reduction in out-of-pocket costs
would also be required if patients needed to use inhalers
more frequently (6% and 3% cost reduction per additional
use of inhaler per day, respectively), or if patients were
required to use additional inhalers (10% and 5% cost
reduction per additional inhaler, respectively; Figure 2).
OR (95% CI)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Ease of use: no mistakesa
Ease of use: some mistakesa
Exacerbationsb
Times per day
medication neededc
Number of inhalersd
No side effectsf
Some side effectsf
Out-of-pocket costse
UK
USA
Germany
Figure 1 Drivers of choice in the discrete choice experiment (DCE).
Notes: A mixed logit model was used. aReference: a lot of mistakes; bPer one exacerbation decrease per year; cPer reduction of one in the number of times the medication
needs to be taken; dPer reduction of one in the number of inhalers needed; ePer 5% decrease in out-of-pocket costs relative to current maintenance therapy cost (not
applicable to the UK); fReference: a lot of side effects.
Abbreviations: CI, confidence interval; DCE, discrete choice experiment; OR, odds ratio; UK, United Kingdom; USA, United States of America.
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Regarding the number of exacerbations, participants in
the UK, USA, and Germany would also require
a reduction in the number of exacerbations per year to
accept a higher frequency of inhaler use (a 0.15, 0.50, and
0.15 reduction per additional use per day, respectively), or
to accept using more inhalers (a 0.35, 0.81, and 0.26
reduction per additional inhaler, respectively; Figure 3).
When presented with an alternative scenario of using
a single inhaler once daily compared with the reference
scenario of two inhalers twice daily, the probability of
participants taking up the alternative scenario was consis-
tent across countries: 59% in the UK and Germany, and
65% in the USA. Participants across all countries would
also be willing to accept an increase in the frequency of
exacerbations per year to accommodate this switch (UK,
0.46 per year; USA, 1.29 per year; Germany, 0.39 per year)
and showed a willingness to pay for a reduction in the
frequency and number of inhalers (Table 4).
Discussion
The results of the DCE suggest that, based on relative
attribute importance, participants with COPD in the UK,
USA, and Germany assign most value to the avoidance
of side effects when choosing a treatment, followed by
likelihood of fewer exacerbations and ease of inhaler
use. While the number of inhalers, out-of-pocket costs,
and frequency of inhaler use were also found to be
important drivers of choice, they were less important
overall. Overall, all attributes of treatment played a role
in participants’ choices. The findings also suggest that
participants would be willing to accept a cost increase
for a regimen that necessitated only a single inhaler once
daily, rather than two inhalers twice daily. With an
increasing number of treatment options now available,
0 5 10 15 20 25
USA
Germany
Exacerbations (per 1 increase per year)
Frequency of inhaler use (per 1 increase per day)
Number of inhalers (per 1 increase)
Cost reduction required to accept treatment, %
Figure 2 Marginal rate of substitution (MRS) for a reduction in cost relative to
current maintenance therapy cost.
Notes: Cost analysis not applicable to the UK. Cost reduction relative to cost of
current medication.
Abbreviations: MRS, marginal rate of substitution; UK, United Kingdom; USA,
United States of America.
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
UK
USA
Frequency of inhaler use (per 1 increase per day)
Number of inhalers (per 1 increase)
0
Germany
Exacerbation reduction required to
accept treatment
Figure 3 Marginal rate of substitution (MRS) for a reduction in exacerbations.
Abbreviations: MRS, marginal rate of substitution; UK, United Kingdom; USA,
United States of America.
Table 4 Uptake Probability, Exacerbation Trade-Off and
Willingness to Pay for a Switch from Two Inhalers Twice Daily
to a Single Inhaler Once Daily
Single Inhaler Once Daily vs
Two Inhalers Twice Daily
UK
(n=150)
USA
(n=150)
Germany
(n=150)
Uptake probability,a % 59 65 59
Increase in the number of
exacerbations during 1 year
that would be accepted to
switch to a single inhaler once
daily
0.46 1.29 0.39
Willingness to pay to switch
to a single inhaler once daily,b
% cost increase
N/A 15.9 9.2
Notes: aThe probability that a patient would choose a single inhaler once daily over
the reference scenario of two inhalers twice daily; bRelative to current maintenance
therapy cost (USA and Germany only).
Abbreviations: N/A, not applicable; UK, United Kingdom; USA, United States of
America.
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including the recent approval of single-inhaler triple
therapies for the treatment of COPD, understanding
patient preferences for certain aspects of treatment
could be used to inform physicians’ prescribing deci-
sions. Additionally, improved understanding of patient
preferences may improve long-term patient adherence
to treatment, and therein may improve patient care.
Further research to explore this postulation may be
beneficial.
Preference heterogeneity, highlighting the variability in
participant responses according to certain participant char-
acteristics, was relatively low in each of the three coun-
tries. In the UK and Germany, participants who had
experienced more exacerbations assigned less importance
to treatments which offered fewer than two exacerbations
per year compared with participants who had experienced
fewer exacerbations. This might be because they have
become used to experiencing exacerbations and are con-
fident in how to handle them (or rather that participants
who had fewer exacerbations had more concerns regarding
their management), although this would not explain why
a similar heterogeneity in preferences was not observed in
patients in the USA. Little heterogeneity was identified for
the interactions between age and the ease of inhaler use
attribute, time since diagnosis and the side effects attri-
bute, or current number of inhalers and the number of
inhalers attribute in each of the three countries. This sug-
gests that, for example, the age of the participant (younger
or older) did not impact on preference for an inhaler that is
easier to use. There was some heterogeneity in the impor-
tance of avoiding side effects, particularly for participants
with different comorbidities since those with more severe
comorbidities assigned less value to the avoidance of side
effects when stating their treatment preferences. However,
this relationship was not consistent for different comorbid-
ities within or across countries. There was also some
evidence of preference heterogeneity between current
inhaler use and the ease of inhaler use attribute for all
countries, although these relationships were also not con-
sistent within or across countries. It is important to note
that between-country comparisons are qualitative and
exploratory only, and no statistical significance of these
country differences was assessed.
The MRS calculations suggest that participants in the
USA and Germany would require a reduction in cost if the
treatment was associated with additional exacerbations,
increased frequency of use, or the need for additional
inhalers. Overall, participants in all three countries would
be willing to accept an increase in exacerbations if they
were required to use their inhaler(s) less often or use fewer
devices overall.
The mean CAT score for study participants was 22.9,
representing the high clinical impact of COPD on the
individuals included.14 While this study has provided
novel insights into the treatment preferences of indivi-
duals with symptomatic COPD, it does have some limita-
tions regarding the methodology and its assumptions. The
DCE did not contain all possible medication characteris-
tics that may influence patient preferences, although our
approach aligns with good practice16,17 in the field and
captured the most important attributes according to
patients. As specific guidance on what constituted a side
effect of their treatment was not provided, individual
participants may have considered different side effects
(eg, sore throat, headache, dry mouth, or oral thrush)
when interpreting the attribute “side effects”, with the
potential for this to influence the level of preference they
assigned to this attribute. Also, as is inherent with this
type of analysis, the results of this study can only be
interpreted within the context of the attribute levels
selected and it is not possible to calculate the effect of
additional levels (eg, level of participant preference for
avoiding treatments requiring administration >3 times
per day) or additional attributes. Participants were
recruited through consumer and medical recruitment net-
works and may have previously volunteered or expressed
interest in participating in research. This could create
some selection bias, which may limit the generalizability
of the findings. The DCE was only hosted online, which
could have limited participation for some patients, parti-
cularly in the older age range. This is an important con-
sideration, given that COPD is more prevalent in older
populations.18,19 As elderly patients are typically under-
represented in clinical trials,20 extrapolation of these DCE
findings to older patients with COPD in real-world clin-
ical practice should be approached with caution.
Conclusions
This study suggests that individuals with COPD in the
UK, USA, and Germany may place the highest value on
the avoidance of side effects, followed by the likelihood
of fewer exacerbations and receiving an inhaler which is
easy to use, when selecting treatment. The benefit of
having to use fewer inhalers and using an inhaler less
frequently are also important considerations. Overall, the
findings were generally consistent across countries,
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although participants in the USA appeared more sensi-
tive to changes in treatment burden, including ease of
inhaler use, than those in the UK and Germany; further
exploration is required to confirm this. Inhaler attributes,
as well as efficacy and safety, appear to be relevant for
patients. Ensuring patient preferences are met when
selecting COPD therapy is important since it may
improve treatment compliance and thus effectiveness.
Abbreviations
CAT, COPD Assessment Test; CI, confidence interval,
COPD, chronic obstructive pulmonary disease; DCE, dis-
crete choice experiment; DPI, dry-powder inhaler; ICS,
inhaled corticosteroid; IQR, interquartile range; IRB, insti-
tutional review board; ISPOR, International Society for
Pharmacoeconomics and Outcomes Research; LABA,
long-acting β2-agonist; LAMA, long-acting muscarinic
antagonist; mMRC, modified Medical Research Council;
MRS, marginal rate of substitution; N/A, not applicable;
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